Paper2Agent automatically transforms static research papers into interactive AI agents that users can query in natural language, eliminating the need to manually install code, configure environments, or parse technical documentation. The system wraps a paper's methods, code, and data as an MCP (Model Context Protocol) server that connects to LLMs like Claude, letting researchers apply the paper's techniques to new problems without programming expertise.

• Paper2Agent solves a real friction point: even well-documented computational methods require substantial setup work (installing dependencies, understanding APIs, configuring parameters), which blocks adoption by researchers without strong technical skills. The system lets users ask questions like "interpret this variant's effect on chromatin accessibility" instead of wrestling with repository setup.
• The framework validates reproducibility by testing each tool against the original paper's reported results and figures, then locks those tools to prevent LLM hallucination and ensure consistent outputs. Every tool includes a code reference back to the original paper for transparency.
• Demonstrated agents successfully reproduced results from AlphaGenome (genomic variant interpretation), Scanpy (single-cell analysis), and TISSUE (spatial transcriptomics), then performed novel analyses like collaborating across multiple agents to prioritize a causal gene for psoriasis.

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

• AWS launched Amazon Bio Discovery, a no-code AI platform letting scientists run drug-design workflows using foundation models plus an AI agent, cutting months of research into weeks.
• In a Memorial Sloan Kettering/Twist Bioscience collaboration, nearly 300,000 AI-designed antibodies were narrowed to 100,000 for physical lab testing.
• Bayer, Broad Institute and Voyager Therapeutics are early adopters, and 19 of the top 20 global pharma companies already use AWS cloud services.
• AWS is separately partnering with Boston Consulting Group and Merck on an AI tool to improve clinical trial site selection.